Cargando…
Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts
Cell line-derived xenografts (CDXs) are an integral part of drug efficacy testing during development of new pharmaceuticals against cancer but their accuracy in predicting clinical responses in patients have been debated. Patient-derived xenografts (PDXs) are thought to be more useful for predictive...
Autores principales: | Bhadury, Joydeep, Einarsdottir, Berglind O., Podraza, Agnieszka, Bagge, Roger Olofsson, Stierner, Ulrika, Ny, Lars, López, Marcela Dávila, Nilsson, Jonas A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029664/ https://www.ncbi.nlm.nih.gov/pubmed/27009863 http://dx.doi.org/10.18632/oncotarget.8181 |
Ejemplares similares
-
Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions
por: Einarsdottir, Berglind O., et al.
Publicado: (2014) -
BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Veppil Muralidharan, Somsundar, et al.
Publicado: (2017) -
BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Muralidharan, Somsundar Veppil, et al.
Publicado: (2017) -
A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma
por: Einarsdottir, Berglind O., et al.
Publicado: (2018) -
Correction: A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma
por: Einarsdottir, Berglind O., et al.
Publicado: (2020)